Yale University

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January

Induced proximity biology – bringing two molecules together to cause some kind of reaction – is in its heyday via the field of targeted protein degradation with proteolysis targeting chimera (PROTAC)

October ended and November began with the announcement of three new venture capital and equity funds with more than $1.3bn for health care, life science and biopharmaceutical investments. Revelation P

Venture capital mega-rounds of $100m or more – like the $245m series A round that Aiolos Bio Inc. announced on 24 October – have played a big part in surging quarterly and annual totals of biopharma